[The Diagnosis is Obvious].

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Clinically amyopathic dermatomyositis (CADM) is a rare subset of dermatomyositis, typically lacking muscle involvement and presenting with normal creatine kinase levels.
• Characteristic dermal manifestations include Gottron's papules and mechanic's hands.
• Association with anti-melanoma differentiation-associated gene 5 (MDa5) antibodies often signifies a severe, rapidly progressive interstitial lung disease (ILD).

Purpose of the Study:

• To review the clinical presentation, diagnostic findings, and therapeutic strategies for CADM, particularly when associated with MDa5 antibodies and interstitial lung disease.
• To highlight the challenges in managing this severe form of ILD and explore novel treatment options.

Main Methods:

• Review of clinical data and literature concerning CADM patients with MDa5 antibodies and ILD.
• Analysis of diagnostic features including pulmonary function tests, high-resolution CT scans, and bronchoalveolar lavage findings.
• Evaluation of treatment outcomes with immunosuppressive therapies and the Janus kinase inhibitor tofacitinib.

Main Results:

• CADM with MDa5 antibodies frequently presents with restrictive lung disease, hypoxemia, and characteristic CT findings like ground-glass opacities and reticulations.
• Pathological findings in the lungs can resemble non-specific interstitial pneumonia or organizing pneumonia.
• Standard immunosuppression is common, but often requires combination therapy; tofacitinib represents a novel therapeutic approach.
• Treatment monitoring involves ferritin levels and MDa5 antibody titers.
• Mortality rates can be as high as 84%.

Conclusions:

• CADM associated with MDa5 antibodies poses a significant risk of severe, rapidly progressive interstitial lung disease with high mortality.
• Prompt diagnosis and aggressive management, potentially including novel agents like tofacitinib, are crucial.
• Further research into optimal treatment strategies and monitoring biomarkers is warranted.